Back to Newsroom
Back to Newsroom

Heat Biologics Reports Third Quarter 2019 Results and Provides Corporate Update

Friday, 15 November 2019 08:30 AM

Heat Biologics, Inc.

Reported Positive Phase 2 Interim Data in Advanced Non-Small Cell Lung Cancer Patients

MORRISVILLE, NC / ACCESSWIRE / November 15, 2019 / Heat Biologics, Inc. (Nasdaq:HTBX), a biopharmaceutical company developing therapeutics designed to activate a patient's immune system against cancer, today reported financial and clinical updates for the third quarter ended September 30, 2019.

Jeff Wolf, Heat's CEO, commented, "We remain encouraged by the positive top line data from our Phase 2 trial for HS-110 in advanced non-small cell lung cancer (NSCLC) in combination with Bristol-Myers Squibb's anti-PD-1 checkpoint inhibitor, Opdivo® (nivolumab) and with Merck's anti-PD-1 checkpoint inhibitor Keytruda® (pembrolizumab), which completed enrollment in July 2019. We recently presented a subset of this data in a poster presentation at The Society of Immunotherapy of Cancer's (SITC) 34th Annual Meeting, in which we reported that 61% of patients in our Phase 2 Cohort B achieved disease stabilization per iRECIST, a patient population whose disease had progressed following prior checkpoint inhibitor therapy. Based on this data, we look forward to advancing our clinical trials and intend to aggressively explore all options for the future development of HS-110, including possible collaboration and licensing opportunities."

"We ended the quarter with approximately $15.0 million in cash, cash equivalents and short-term investments. We believe we are well funded to advance our clinical activities though additional major milestones and continue to manage expenses accordingly."

Third Quarter 2019 Financial Results

  • Research and development expenses decreased to $3.1 million for the quarter ended September 30, 2019 compared to $4.4 million for the quarter ended September 30, 2018. The decrease of approximately $1.3 million is due to the lower PTX-35 expense for 2019, primarily reflecting decreased manufacturing costs, offset by increased Phase 2 trial expenses, including outsourced clinical trial support services and payments to investigator sites.
  • General and administrative expense increased to $2.0 million for the quarter ended September 30, 2019 compared to $1.6 million for the quarter ended September 30, 2018. The $0.4 million increase is primarily attributable to increased personnel costs, including stock-based compensation expense.
  • Net loss attributable to Heat Biologics was approximately $6.2 million, or ($0.18) per basic and diluted share for the quarter ended September 30, 2019 compared to a net loss of approximately $3.7 million, or ($0.16) per basic and diluted share for the quarter ended September 30, 2018.
  • As of September 30, 2019, the Company had approximately $15.0 million in cash, cash equivalents and short-term investments with an additional $6.9 million in grant funds from Cancer Prevention Research Institute of Texas (CPRIT) that it expects to receive after filing an IND for PTX-35.

About Heat Biologics, Inc.

Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer using CD8+ "Killer" T-cells. HS-110 is the Company's first biologic product candidate in a series of proprietary immunotherapies designed to stimulate a patient's own T-cells to attack cancer. Heat has completed enrollment in its Phase 2 clinical trial for advanced non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®) or with Merck's pembrolizumab (Keytruda®). Pelican Therapeutics, a subsidiary of Heat, is focused on the development of co-stimulatory monoclonal antibody and fusion protein-based therapies designed to activate the immune system. Heat also has numerous pre-clinical programs at various stages of development. For more information, please visit

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and include statements such as: looking forward to advancing Heat's clinical trials, the intention to aggressively explore all options for the future development of HS-110, including possible collaboration and licensing opportunities, being well funded to advance Heat's clinical activities through additional major milestones and continuing to manage expenses accordingly, and the expected receipt of an additional $6.9 million in grant funds from CPRIT after filing the IND for PTX-35 These statements are based on management's expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements, including the ability of Heat's therapies to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, Heat's ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Heat's ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, Heat's ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, its ability to retain its key scientists or management personnel, and the other factors described in Heat's Annual Report on Form 10-K and 10-K/A for the year ended December 31, 2018 and other subsequent filings with the SEC. The information in this release is provided only as of the date of this release and the company undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

Media and Investor Relations Contact

David Waldman
[email protected]

(tables follow)


Consolidated Balance Sheets

September 30,
December 31,
Current Assets
Cash and cash equivalents
  9,334,421     22,154,251  
Short-term investments
    5,683,446       5,570,027  
Accounts receivable
    37,300       28,538  
Prepaid expenses and other current assets
    734,788       961,317  
Total Current Assets
    15,789,955       28,714,133  
Property and Equipment, net
    609,916       643,146  
Other Assets
In-process R&D
    5,866,000       5,866,000  
    1,452,338       2,189,338  
Right-of-use asset
    347,153       -  
    386,284       351,220  
Total Other Assets
    8,051,775       8,406,558  
Total Assets
  24,451,646     37,763,837  
Liabilities and Stockholders' Equity
Current Liabilities
Accounts payable
  1,944,333     974,619  
Deferred revenue
    -       1,032,539  
Contingent consideration, current portion
    1,477,000       1,187,000  
Operating lease liability, current portion
    91,068       -  
Accrued expenses and other liabilities
    1,281,911       1,678,051  
Total Current Liabilities
    4,794,312       4,872,209  
Long Term Liabilities
Contingent consideration
    2,356,515       1,918,225  
Deferred tax liability
    361,911       316,733  
Deferred revenue, net of current portion
    200,000       200,000  
Operating lease liability, net of current portion
    259,222       -  
Other long-term liabilities
    306,235       213,724  
Total Liabilities
    8,278,195       7,520,891  
Commitments and Contingencies
Stockholders' Equity
Common stock, $.0002 par value; 100,000,000 shares authorized, 33,334,124 and 32,492,144 shares issued and outstanding at September 30, 2019 (unaudited) and December 31, 2018, respectively
    6,822       6,499  
Additional paid-in capital
    117,836,082       114,883,135  
Accumulated deficit
    (101,261,124 )     (84,580,180 )
Accumulated other comprehensive loss
    52,230       (19,904 )
Total Stockholders' Equity- Heat Biologics, Inc.
    16,634,010       30,289,550  
Non-Controlling Interest
    (460,559 )     (46,604 )
Total Stockholders' Equity
    16,173,451       30,242,946  
Total Liabilities and Stockholders' Equity
  24,451,646     37,763,837  


Consolidated Statements of Operations and Comprehensive Loss

  Three Months Ended,
September 30,
    Nine months Ended,
September 30,
  2019     2018     2019     2018  
Grant and licensing revenue
  6,439     1,840,009     1,049,988     3,735,713  
Operating expenses:
Research and development
    3,129,356       4,403,759       9,725,744       10,756,485  
General and administrative
    1,993,136       1,585,600       7,201,196       4,727,105  
Goodwill impairment loss
    737,000       -       737,000       -  
Change in fair value of contingent consideration
    502,000       114,838       728,290       665,936  
Total operating expenses
    6,361,492       6,104,197       18,392,230       16,149,526  
Loss from operations
    (6,355,053 )     (4,264,188 )     (17,342,242 )     (12,413,813 )
Interest income
    97,415       83,509       373,060       131,306  
Other (expense) income, net
    (73,275 )     31,704       (80,539 )     153,500  
Total non-operating income
    24,140       115,213       292,521       284,806  
Net loss before income taxes
    (6,330,913 )     (4,148,975 )     (17,049,721 )     (12,129,007 )
Income tax benefit (expense)
    -       225,389       (45,178 )     665,080  
Net loss
    (6,330,913 )     (3,923,586 )     (17,094,899 )     (11,463,927 )
Net loss - non-controlling interest
    (136,315 )     (265,024 )     (413,955 )     (668,219 )
Net loss attributable to Heat Biologics, Inc.
  (6,194,598 )   (3,658,562 )   (16,680,944 )   (10,795,708 )
Net loss per share attributable to Heat Biologics, Inc.-basic and diluted
  (0.18 )   (0.16 )   (0.50 )   (0.75 )
Weighted-average number of common shares used in net loss per share attributable to Heat Biologics, Inc.-basic and diluted
    33,650,829       23,143,952       33,255,535       14,359,429  
Other comprehensive loss:
Net loss
  (6,330,913 )   (3,923,586 )   (17,094,899 )   (11,463,927 )
Unrealized gain on foreign currency translation
    63,711       39,377       72,134       110,648  
Total other comprehensive loss
    (6,267,202 )     (3,884,209 )     (17,022,765 )     (11,353,279 )
Comprehensive loss attributable to non-controlling interest
    (136,315 )     (265,024 )     (413,955 )     (668,219 )
Comprehensive loss
  (6,130,887 )   (3,619,185 )   (16,608,810 )   (10,685,060 )

SOURCE: Heat Biologics, Inc.

Company Update
Back to newsroom
Back to Newsroom
Share by: